Particulate and drug-induced toxicity assessed in novel quadruple cell human primary hepatic disease models of steatosis and pre-fibrotic NASH
A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates
Digital pathology with artificial intelligence analysis provides insight to the efficacy of anti-fibrotic compounds in human 3D MASH model
Sweet and sticky: increased cell adhesion through click-mediated functionalization of regenerative liver progenitor cells
4D live imaging and computational modeling of a functional gut-on-a-chip evaluate how peristalsis facilitates enteric pathogen invasion
Quris.AI
Quris.AI is transforming drug safety prediction by uniquely combining advanced AI capabilities with cutting edge 3D organ models, enabling predictions with unprecedented accuracy and scalability. our platform has been extensively validated by leading Pharma companies, including a long term collaboration with Merck GmbH. By predicting safety in human relevant 3D models, our platform significantly increases the likelihood of clinical success and reduces significantly the need for animal testing.
A new immortalized human alveolar epithelial cell model to study lung injury and toxicity on a breathing lung-on-chip system
Optics11
Optics11Life develops cutting-edge life science tools using optical fiber sensing technology. The two main products are: The Nanoindentation Platform (Pavone, Piuma and Chiaro) and The Cuore 3D Engineered Muscle Contractility Platform
PredictCan Biotechnologies
“PredictCan Biotechnologies has patented cell education technology that exploits the intrinsic plasticity of cell lines by inducing subject-dependent phenotypic changes to better model cohorts of healthy or pathological individuals with tailored characteristics. The company generates state-of-the-art 3D individual-centric models for early detection of cancers, drug discovery, drug safety, and drug efficacy. Among our models, GenuineSelect-TOX is a platform that accurately detects intrinsic DILI and immune-mediated idiosyncratic DILI (iDILI) during the early and late stages of drug development.